Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | ADK | P55263 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | USP1 | O94782 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8667511 | 0.86 | CSNK1A1 (0.50) | ADRA2AADRA2BADRA2CCSNK1A1TYRO3 | |
| SCHEMBL27733927 | 0.85 | TAAR1 (0.49) | ADRA2AADRA2BADRA2CCSNK1A1TYRO3 | |
| SCHEMBL20150086 | 0.81 | TAAR1 (0.46) | ADRA2AADRA2BADRA2CCSNK1A1TYRO3 | |
| SCHEMBL9287236 | 0.80 | NISCH (0.64) | ADRA2AADRA2BADRA2CCSNK1A1TYRO3 | |
| SCHEMBL2821845 | 0.80 | TAAR1 (0.54) | ADRA2AADRA2BADRA2CCSNK1A1TYRO3 | |
| SCHEMBL19154033 | 0.79 | USP1 (0.37) | ADRA2AADRA2BADRA2CCSNK1A1TYRO3 | |
| Bromide SCHEMBL31606836 | 0.79 | TAAR1 (0.53) | ADRA2AADRA2BADRA2CCSNK1A1TYRO3 | |
| Hydrochloric Acid SCHEMBL28055288 | 0.79 | TAAR1 (0.53) | ADRA2AADRA2BADRA2CCSNK1A1TYRO3 | |
| SCHEMBL14886257 | 0.78 | NISCH (0.61) | ADRA2AADRA2BADRA2CCSNK1A1TYRO3 | |
| SCHEMBL3851903 | 0.77 | CSNK1A1 (0.48) | ADRA2AADRA2BADRA2CCSNK1A1TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0893985-B1 | KERATIN FIBRE DYE COMPOSITIONS CONTAINING IMIDAZOLO-AZOLE COMPOUNDS, USE THEREOF AS DYE COUPLERS, AND DYEING METHOD | OREAL (FR) | 2000-04-12 | — | — | EP | claimed |
| EP-0893985-A1 | KERATIN FIBRE DYE COMPOSITIONS CONTAINING IMIDAZOLO-AZOLE COMPOUNDS, USE THEREOF AS DYE COUPLERS, AND DYEING METHOD | L'OREAL (FR) | 1999-02-03 | — | — | EP | claimed |
| WO-1997035552-A1 | KERATIN FIBRE DYE COMPOSITIONS CONTAINING IMIDAZOLO-AZOLE COMPOUNDS, USE THEREOF AS DYE COUPLERS, AND DYEING METHOD | L'OREAL (FR) | 1997-10-02 | — | — | WO | claimed |
| CN-103145769-B | Bis-cyclometallated compound of heteronuclear ruthenium palladium and its preparation method and application | HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-03-02 | — | — | CN | disclosed |
| CN-103159802-B | Heteronuclear ruthenium-gold bicyclic metal compound and its preparation method and use | UNIV HENAN SCIENCE & TECH | 2015-02-25 | — | — | CN | disclosed |
| CN-103012504-B | Heteronuclear palladium gold bicyclo metal compound as well as preparation method and application of compound | UNIV LUOYANG NORMAL | 2015-02-25 | — | — | CN | disclosed |
| US-8748433-B2 | β3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8501786-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| CN-103159802-A | Heteronuclear ruthenium-gold bicyclic metal compound and its preparation method and use | UNIV HENAN SCIENCE & TECH | 2013-06-19 | — | — | CN | disclosed |
| US-20130053403-A1 | NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053403-A1 | NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
| US-7592456-B2 | Arylsulfonylnaphthalene derivatives as 5HT2A antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7592456-B2 | Arylsulfonylnaphthalene derivatives as 5HT2A antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| CN-101238121-A | Fused bicyclic heterocycle substituted quinuclidine derivatives | ABBOTT LAB (US) | 2008-08-06 | — | — | CN | disclosed |
| US-20070281952-A1 | Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists | MERCK SHARPE & DOHME LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281952-A1 | Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists | MERCK SHARPE & DOHME LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| CN-1922176-A | Condensed bicycle heterocycle substituted quinuclidine derivant | ABBOTT LAB (US) | 2007-02-28 | — | — | CN | disclosed |
| EP-0893985-B1 | KERATIN FIBRE DYE COMPOSITIONS CONTAINING IMIDAZOLO-AZOLE COMPOUNDS, USE THEREOF AS DYE COUPLERS, AND DYEING METHOD | OREAL (FR) | 2000-04-12 | — | — | EP | disclosed |
| EP-0893985-A1 | KERATIN FIBRE DYE COMPOSITIONS CONTAINING IMIDAZOLO-AZOLE COMPOUNDS, USE THEREOF AS DYE COUPLERS, AND DYEING METHOD | L'OREAL (FR) | 1999-02-03 | — | — | EP | disclosed |
| WO-1997035552-A1 | KERATIN FIBRE DYE COMPOSITIONS CONTAINING IMIDAZOLO-AZOLE COMPOUNDS, USE THEREOF AS DYE COUPLERS, AND DYEING METHOD | L'OREAL (FR) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053403-A1 | NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | ADRA2A 8/4885ADRA2B 4/4885ADRA2C 6/4885 |
| US-20070281952-A1 | Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists | HTR2A, HTR2C, HTR1A | ADRA2A 23/4885ADRA2B 27/4885ADRA2C 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.